Related Experiment Video
Updated: Aug 8, 2026
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
Systematical Mutational Analysis of FRATtide against Osteoclast Differentiation by Alanine Scanning
Yi Yang1,2, Chenchen Geng1,2, Huaxing Shen3
1School of Pharmacy, Anhui Medical University, HeFei 230032, China.
Abstract:
Osteoporosis, a global bone disease, results in decreased bone density, mass, and microarchitecture deterioration, increasing fracture risk. In previous research, FRATtide, a peptide derived from a glycogen synthase kinase-3 binding protein, effectively hindered osteoclast differentiation to yield therapeutically potent derivatives via single and double stapling. However, FRATtide's structure-activity relationship remains unclear. This study synthesized 25 FRATtide-derived peptides through systematic alanine scanning and evaluated their activities. Substitutions in Pro2, Leu5, Leu9, Val10, Leu11, Ser12, Asn14, Leu15, Ile16, Glu18, Arg22, Ser25, and Arg26 showed reduced activity, while FRT13 and FRT20 with Gly13 and Arg21 substitutions, respectively, displayed enhanced activities. F-actin binding and bone resorption assays on FRT13 and FRT20 showed better inhibition of osteoclast differentiation and bone resorption compared with FRATtide. This study elucidated FRATtide's structure-activity relationship, thereby facilitating future structural optimization for osteoporosis treatment.
Insights
Researchers explored FRATtide peptide derivatives for osteoporosis treatment. Specific substitutions enhanced activity, leading to improved inhibition of osteoclast differentiation and bone resorption, aiding future osteoporosis drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Osteoporosis is a global bone disease characterized by decreased bone density and microarchitecture deterioration, increasing fracture risk.
- FRATtide, a peptide derived from a glycogen synthase kinase-3 binding protein, has shown potential in hindering osteoclast differentiation for osteoporosis therapy.
- The precise structure-activity relationship of FRATtide remains incompletely understood, limiting further optimization.
Purpose of the Study:
- To elucidate the structure-activity relationship of FRATtide by synthesizing and evaluating FRATtide-derived peptides.
- To identify specific amino acid substitutions that enhance the anti-osteoporotic activity of FRATtide.
- To facilitate the future structural optimization of FRATtide for improved osteoporosis treatment.
Main Methods:
- Systematic alanine scanning was employed to synthesize 25 FRATtide-derived peptides.
- The biological activities of synthesized peptides were evaluated through various assays.
- F-actin binding and bone resorption assays were performed on promising derivatives.
Main Results:
- Alanine scanning identified key residues (Pro², Leu⁵, Leu⁹, Val¹⁰, Leu¹¹, Ser¹², Asn¹⁴, Leu¹⁵, Ile¹⁶, Glu¹⁸, Arg²², Ser²⁵, Arg²⁶) whose substitutions reduced activity.
- Peptides FRT13 (Gly¹³ substitution) and FRT20 (Arg²¹ substitution) exhibited enhanced activities compared to the parent FRATtide.
- FRT13 and FRT20 demonstrated superior inhibition of osteoclast differentiation and bone resorption in functional assays.
Conclusions:
- The study successfully elucidated the structure-activity relationship of FRATtide.
- Specific amino acid substitutions, particularly at positions 13 and 21, can significantly enhance the therapeutic potential of FRATtide derivatives.
- These findings provide a foundation for the rational design and structural optimization of novel peptide-based therapeutics for osteoporosis.
